Zymeworks Inc Common Stock

Yahoo Finance • 2 days ago

Bitcoin Miner Leads Two Health Care Stocks To New Highs

Core Scientific hit an all-time high in Friday's stock market. Shares are on a three-day winning streak and just above a cup base's buy point of 18.21, making the company one that's reaching new highs and worth watching. Its relative stren... Full story

Yahoo Finance • 2 days ago

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded NetEase (NTES) to Ov... Full story

Yahoo Finance • 3 days ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 2 months ago

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 2 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Zymeworks sees revenue surge in Q2 2025

Zymeworks Inc. reported a significant increase in revenue for the second quarter of 2025, achieving $48.7 million compared to $19.2 million in the same period last year. This growth was driven by key milestone payments and deferred revenue... Full story

Yahoo Finance • 2 months ago

Zymeworks GAAP EPS of $0.03 beats by $0.52, revenue of $48.7M beats by $31.52M

* Zymeworks press release [https://seekingalpha.com/pr/20194039-zymeworks-provides-corporate-update-and-reports-second-quarter-2025-financial-results] (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]): Q2 GAAP EPS of $0.03 beats by $0... Full story

Yahoo Finance • 2 months ago

Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance

[Human liver cancer concept, liver cirrhosis] * The U.S. FDA has cleared an Investigational new drug application (IND) for Zymeworks' (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]) ZW251, an antibody-drug conjugate for the treatme... Full story

Yahoo Finance • 3 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favorable tolerability profilePhase 1 clinica... Full story

Yahoo Finance • 3 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 3 months ago

Zymeworks stock holds steady as H.C. Wainwright reiterates Neutral rating

Investing.com - H.C. Wainwright has reiterated its Neutral rating and $13.00 price target on Zymeworks (NASDAQ:ZYME) following recent developments with its zanidatamab therapy. The company, currently trading near $12.89, has delivered an i... Full story

Yahoo Finance • 4 months ago

Zymeworks gets China's conditional approval for biliary tract cancer treatment

[Cancer cells vis] koto_feja/E+ via Getty Images * Zymeworks (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]) said on Friday that the China health regulator has given conditional approval to zanidatamab for the treatment of metastat... Full story

Yahoo Finance • 4 months ago

Zymeworks Gets China's NMPA Approval For Zanidatamab

(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biotechnology company, Friday said that the National Medical Products Administration (NMPA) in China has approved zanidatamab for the treatment of HER2-high expression (IHC3+) biliary tra... Full story

Yahoo Finance • 4 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study$20 million milestone payment to be re... Full story

Yahoo Finance • 5 months ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to... Full story

Yahoo Finance • 5 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel bispecific design shows promising poten... Full story

Yahoo Finance • 5 months ago

Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...

Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zymeworks Inc (NASDAQ:ZYME) reported a significant increase in revenue for Q1 2025, reaching... Full story

Yahoo Finance • 6 months ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story